… treatment effects of dapagliflozin by age either when analyzed at the median age cutpoint or
when analyzed continuously (P interaction >0.20 for both). Treatment effects of dapagliflozin …

… We also examined the effects of dapagliflozin compared with placebo on clinical events
according to FI among patients with no missing data for any of the components of the FI. The …

… Although the effects of dapagliflozin on clinical outcomes were consistent across the range
of FI in DELIVER (0 to 0.633), our results may not be generalizable to all patients with HF, …

… It should therefore be acknowledged that the time to statistical significance of the clinical
benefit may be a consequence not only of the pharmacodynamic effects of dapagliflozin but …

… in clinical management of heart failure, with or … heart failure with reduced ejection fraction
and highlight the need for further research on uses of dapagliflozin in the world of heart failure…

… for heart failure, ESKD or all-cause death, ESKD, or heart failure hospitalization; a … heart
failure, or cardiovascular death; and a composite of ESKD, hospitalization for heart failure…

… Finally, to assess whether the change in SBP accounted for the beneficial effects of
dapagliflozin, we generated Cox models assessing the relationship between treatment assignment …

… The beneficial effects of dapagliflozin compared with placebo on … Key words: Heart failure;
chronic obstructive pulmonary … Effects of dapagliflozin in heart failure with reduced ejection …

… considerations—how the patients randomized in DAPA-HF and their event rates compare
with those in the prior SGLT2 inhibitor trials and, second, how the effects of dapagliflozin …

… Treatment effects of dapagliflozin on the primary outcome were, however consistent when
assessed across the modified Heart Failure Collaboratory Medical Therapy Score integrating …